Artivion (AORT) Q4 2025 earnings review
Profitability Inflection Driven by AMDS Launch
Artivion closed FY25 with a decisive pivot to GAAP profitability, delivering Net Income of $2.4M compared to a $(16.5)M loss a year ago. The quarter was defined by massive uptake in Aortic Stent Grafts (+36% constant currency), confirming the AMDS launch as a transformative catalyst. While Surgical Sealants stagnated (0% growth), the company successfully leveraged 18% top-line growth into a 29% surge in Adjusted EBITDA, validating their '2x revenue growth' leverage model. FY26 guidance projects continued double-digit expansion, signaling the growth story remains intact.
🐂 Bull Case
The Stent Graft segment accelerated to 44% YoY reported growth (36% constant currency). The U.S. AMDS launch is not just an incremental driver; it is actively reshaping the company's revenue mix towards higher-margin devices.
Artivion swung from a $(16.5)M loss in 24Q4 to a $2.4M profit in 25Q4. This proves the business model can generate real earnings, not just adjusted metrics, even while investing in product launches.
🐻 Bear Case
BioGlue/Sealants revenue was flat (0% constant currency growth). As a core segment, this lack of momentum drags on overall performance and increases reliance on Stent Grafts to carry the quarter.
The company recorded a $2.3M liability regarding Italian government payback legislation. While treated as a one-off revenue reduction, European regulatory clawbacks remain an unpredictable headwind for med-tech.
⚖️ Verdict: 🟢🟢
Bullish. The shift to GAAP profitability combined with >30% growth in the Stent Graft segment outweighs the stagnation in BioGlue. The operational leverage thesis is playing out exactly as management promised.
Key Themes
Stent Graft Acceleration
Accelerating. The Stent Graft segment is the clear engine of the company, growing 36% YoY in constant currency to $43.3M. This acceleration (up from 31% in Q3) confirms that the AMDS launch is gaining momentum and likely driving cross-selling synergies.
On-X Valve Renaissance
Stable. On-X revenues grew 24% YoY (constant currency), maintaining the high-20s growth pace seen in previous quarters (23% in Q3). Clinical data favoring mechanical valves in patients under 65 continues to drive a secular shift in usage, insulating this segment from broader market pressures.
BioGlue Drag
Decelerating. Surgical Sealants revenue came in flat (0% growth) on a constant currency basis. This segment has deteriorated sequentially from 9% growth in Q1 to 0% in Q4. Management previously cited distributor stocking variability, but a flat result suggests potential saturation or competitive pressure.
Regulatory Headwinds (Italy)
A $2.3M revenue reduction was recorded due to Italian legislation requiring medical device companies to pay back expenditures exceeding regional ceilings (2019-2025). This hit GAAP revenue and highlights the geopolitical risks in the European pricing environment.
Pipeline Maturation
The company filed the final module for the AMDS PMA application and presented positive data for the NEXUS TRIOMPHE trial (94% survival). These milestones de-risk the mid-term growth outlook beyond the current AMDS HDE launch.
Other KPIs
Reversing. A massive swing from a $(16.5)M loss in the prior year period. Full year 2025 GAAP Net Income reached $9.8M vs a $(13.4)M loss in 2024. This validates the company's ability to control costs while scaling revenue.
Expanding. Calculated as $22.7M / $116.0M. While Q4 shows strong YoY growth in EBITDA dollars (+29%), the margin slightly compressed sequentially from Q3 (~21.7%), likely due to end-of-year sales mix or timing of expenses, but remains well above the ~18% seen in 24Q4.
Guidance
Stable. The guidance implies 10-14% constant currency growth, consistent with the 13% growth achieved in FY25. This suggests management sees the current momentum as sustainable but not necessarily accelerating further from this high base.
Decelerating. The guidance implies 18-22% growth. While strong, this is a deceleration from the 26% growth achieved in FY25. However, it still adheres to the company's 'grow EBITDA at 2x revenue' framework.
Key Questions
BioGlue Growth Strategy
Surgical sealants growth flatlined at 0% in Q4. Is this purely a stocking issue, or are we seeing competitive saturation in core markets?
Italian Payback Exposure
Does the $2.3M reserve fully cover the exposure for 2019-2025, or should investors brace for further retrospective adjustments in Italy or other European jurisdictions?
Cash Conversion
With GAAP net income positive, when does management expect Free Cash Flow to consistently match the trajectory of Adjusted EBITDA?